Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial

医学 紫杉醇 微气泡 卡铂 药代动力学 白蛋白 胶质瘤 临床终点 人口 泌尿科 血脑屏障 超声波 外科 内科学 临床试验 化疗 放射科 癌症研究 顺铂 中枢神经系统 环境卫生
作者
Adam M. Sonabend,Andrew Gould,Christina Amidei,Rachel Ward,Karyn A Schmidt,Daniel Y. Zhang,Cristal Gomez,John F. Bebawy,Benjamin P. Liu,Guillaume Bouchoux,Carole Desseaux,Irene Helenowski,Rimas V. Lukas,Karan Dixit,Priya Kumthekar,Víctor A. Arrieta,Maciej S. Lesniak,Alexandre Carpentier,Hui Zhang,Miguel Muzzio
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (5): 509-522 被引量:130
标识
DOI:10.1016/s1470-2045(23)00112-2
摘要

Summary

Background

Low-intensity pulsed ultrasound with concomitant administration of intravenous microbubbles (LIPU-MB) can be used to open the blood–brain barrier. We aimed to assess the safety and pharmacokinetics of LIPU-MB to enhance the delivery of albumin-bound paclitaxel to the peritumoural brain of patients with recurrent glioblastoma.

Methods

We conducted a dose-escalation phase 1 clinical trial in adults (aged ≥18 years) with recurrent glioblastoma, a tumour diameter of 70 mm or smaller, and a Karnofsky performance status of at least 70. A nine-emitter ultrasound device was implanted into a skull window after tumour resection. LIPU-MB with intravenous albumin-bound paclitaxel infusion was done every 3 weeks for up to six cycles. Six dose levels of albumin-bound paclitaxel (40 mg/m2, 80 mg/m2, 135 mg/m2, 175 mg/m2, 215 mg/m2, and 260 mg/m2) were evaluated. The primary endpoint was dose-limiting toxicity occurring during the first cycle of sonication and albumin-bound paclitaxel chemotherapy. Safety was assessed in all treated patients. Analyses were done in the per-protocol population. Blood–brain barrier opening was investigated by MRI before and after sonication. We also did pharmacokinetic analyses of LIPU-MB in a subgroup of patients from the current study and a subgroup of patients who received carboplatin as part of a similar trial (NCT03744026). This study is registered with ClinicalTrials.gov, NCT04528680, and a phase 2 trial is currently open for accrual.

Findings

17 patients (nine men and eight women) were enrolled between Oct 29, 2020, and Feb 21, 2022. As of data cutoff on Sept 6, 2022, median follow-up was 11·89 months (IQR 11·12–12·78). One patient was treated per dose level of albumin-bound paclitaxel for levels 1 to 5 (40–215 mg/m2), and 12 patients were treated at dose level 6 (260 mg/m2). A total of 68 cycles of LIPU-MB-based blood–brain barrier opening were done (median 3 cycles per patient [range 2–6]). At a dose of 260 mg/m2, encephalopathy (grade 3) occurred in one (8%) of 12 patients during the first cycle (considered a dose-limiting toxicity), and in one other patient during the second cycle (grade 2). In both cases, the toxicity resolved and treatment continued at a lower dose of albumin-bound paclitaxel, with a dose of 175 mg/m2 in the case of the grade 3 encephalopathy, and to 215 mg/m2 in the case of the grade 2 encephalopathy. Grade 2 peripheral neuropathy was observed in one patient during the third cycle of 260 mg/m2 albumin-bound paclitaxel. No progressive neurological deficits attributed to LIPU-MB were observed. LIPU-MB-based blood–brain barrier opening was most commonly associated with immediate yet transient grade 1–2 headache (12 [71%] of 17 patients). The most common grade 3–4 treatment-emergent adverse events were neutropenia (eight [47%]), leukopenia (five [29%]), and hypertension (five [29%]). No treatment-related deaths occurred during the study. Imaging analysis showed blood–brain barrier opening in the brain regions targeted by LIPU-MB, which diminished over the first 1 h after sonication. Pharmacokinetic analyses showed that LIPU-MB led to increases in the mean brain parenchymal concentrations of albumin-bound paclitaxel (from 0·037 μM [95% CI 0·022–0·063] in non-sonicated brain to 0·139 μM [0·083–0·232] in sonicated brain [3·7-times increase], p<0·0001) and carboplatin (from 0·991 μM [0·562–1·747] in non-sonicated brain to 5·878 μM [3·462–9·980] μM in sonicated brain [5·9-times increase], p=0·0001).

Interpretation

LIPU-MB using a skull-implantable ultrasound device transiently opens the blood–brain barrier allowing for safe, repeated penetration of cytotoxic drugs into the brain. This study has prompted a subsequent phase 2 study combining LIPU-MB with albumin-bound paclitaxel plus carboplatin (NCT04528680), which is ongoing.

Funding

National Institutes of Health and National Cancer Institute, Moceri Family Foundation, and the Panattoni family.

Video Abstract

Repeated blood–brain barrier opening with an implantable ultrasound device
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xinjie发布了新的文献求助10
刚刚
2秒前
蛋花肉圆汤完成签到,获得积分10
2秒前
羞涩的文轩完成签到 ,获得积分10
3秒前
8秒前
9秒前
北城完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助10
11秒前
14秒前
爱听歌电灯胆完成签到 ,获得积分10
14秒前
不爱吃西葫芦完成签到 ,获得积分10
15秒前
申燕婷完成签到 ,获得积分10
16秒前
橙子完成签到 ,获得积分10
18秒前
ruochenzu发布了新的文献求助10
18秒前
fusheng完成签到 ,获得积分10
27秒前
浮生完成签到 ,获得积分10
32秒前
xinjie完成签到,获得积分10
34秒前
Will完成签到,获得积分10
39秒前
cuddly完成签到 ,获得积分10
40秒前
掉头发的小白完成签到,获得积分10
41秒前
不想看文献完成签到 ,获得积分10
44秒前
45秒前
当女遇到乔完成签到 ,获得积分10
45秒前
独行者完成签到,获得积分10
46秒前
眼睛大的电脑完成签到,获得积分10
46秒前
48秒前
敏敏发布了新的文献求助10
49秒前
木木完成签到 ,获得积分10
50秒前
量子星尘发布了新的文献求助10
50秒前
JamesPei应助科研通管家采纳,获得10
51秒前
彭于晏应助科研通管家采纳,获得10
51秒前
如意2023完成签到 ,获得积分10
51秒前
fomo完成签到,获得积分10
55秒前
nagi发布了新的文献求助10
58秒前
jfeng完成签到,获得积分10
1分钟前
JN完成签到,获得积分10
1分钟前
忐忑的书桃完成签到 ,获得积分10
1分钟前
qaplay完成签到 ,获得积分0
1分钟前
友好语风完成签到,获得积分10
1分钟前
CLTTTt完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022